PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 25, 2026International Journal of Molecular Sciences0 citationsOpen Access

Hypoxia Increases Connexin46 and Connexin43 Levels in KNS-42 Glioblastoma Cells

View Full Paper
PMPeter J. MinogueEBEric C. BeyerVBViviana M. Berthoud

Key Points

  • The research aims to explore how hypoxia and chemotherapy affect connexin levels in glioblastoma cells.
  • Utilized KNS-42 glioblastoma cell line to examine connexin levels.
  • Assessed response to hypoxia and temozolomide treatment.
  • Measured connexin levels and proteasomal activity under different conditions.
  • Prolonged hypoxia increased levels of connexin46 and connexin43.
  • Temozolomide treatment led to decreased connexin43 and increased connexin46 in resistant cells.
  • Hypoxia decreased proteasomal activity without affecting connexin mRNA levels.

Abstract

Glioblastoma multiforme is a devastating brain tumor that frequently progresses or recurs despite therapy. We used the glioblastoma-derived cell line, KNS-42, to study the response of the gap junction proteins, connexin46 and connexin43, to chemotherapeutic agents and to prolonged hypoxia to mimic conditions within the tumor microenvironment. Under standard culture conditions, KNS-42 cells have high levels of connexin43 and very low levels of connexin46. The cells that survived temozolomide treatment had increased connexin46 levels and decreased connexin43 levels. In contrast, prolonged hypoxia increased the levels of both connexins, the number of connexin immunopositive cells, and the intensity of the immunofluorescence signal per cell (which localized preferentially in the cytoplasm). Exposure to hypoxia for 12 days decreased the chymotrypsin-like proteasomal activity without altering connexin mRNA levels, suggesting that the changes in connexin levels result from reduced protein degradation. The increased connexin46 in temozolomide-resistant cells suggests that this connexin may have a role in chemotherapy resistance. The results also imply that changes in the microenvironment of glioblastomas (like hypoxia) can alter proteasomal activity and affect levels and subcellular distribution of connexin46 and connexin43. Finally, our data suggest that proteasomal inhibition may not be a good approach to glioblastoma therapy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Minogue et al. (2026) studied this question.

synapsesocial.com/papers/69c37bd4b34aaaeb1a67ea86https://doi.org/10.3390/ijms27062851
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Connexin 43 drives glioblastoma cancer stem cell phenotypes through a WNK lysine-deficient protein kinase 1-c-MYC signaling axis2024 · 3 citations
  2. 2Tetralol derivative NNC-55-0396 targets hypoxic cells in the glioblastoma microenvironment: an organ-on-chip approach2024 · 13 citations
  3. 3Connexin hemichannels as therapeutic targets in glioblastoma2026
  4. 4TMIC-45. Hypoxia dysregulates the epigenetic landscape and impairs the functions of glioma-associated myeloid cells2025
  5. 5Integrative Transcriptomic Analysis Identifies Hypoxia-Responsive Cell Cycle Hub Genes as Prognostic Markers in Glioblastoma2025